Better ICU palliative support for older adults and their families

Improving Needs Among Older Adults: the ICUconnect 2 Primary Palliative Care RCT

NA · Duke University · NCT06588556

This trial will test whether a mobile app called ICUconnect helps older adults in the ICU and their family caregivers get the palliative care support they need compared with usual care.

Quick facts

PhaseNA
Study typeInterventional
Enrollment350 (estimated)
Ages18 Years and up
SexAll
SponsorDuke University (other)
Locations4 sites (Birmingham, Alabama and 3 other locations)
Trial IDNCT06588556 on ClinicalTrials.gov

What this trial studies

ICUconnect is a mobile app that lets families and patients report palliative care needs across core domains and gives ICU clinicians a scalable digital platform to coordinate targeted care and role-specific informational supports. In this randomized controlled trial, 350 patient–family member dyads with elevated unmet palliative needs will be enrolled across multiple sites and randomized to ICUconnect or usual care. Eligible patients are adults in medical, cardiac, trauma, surgical, or neurological ICUs who are expected to require invasive mechanical ventilation for two or more days, and enrollment centers on the adult family member who provides the most support. The trial expands on a prior single-center cluster RCT that showed improvements in unmet needs and goal concordance and includes linguistic and cultural adaptation for Latin American Spanish.

Who should consider this trial

Good fit: Adults in medical, cardiac, trauma, surgical, or neurological ICUs expected to need invasive mechanical ventilation for two or more days, together with an adult family member who provides the most support, are the intended participants.

Not a fit: Patients expected to die or transition to full comfort-only care within 24 hours, those not expected to require prolonged mechanical ventilation, or those without an identifiable supporting family member are unlikely to benefit from this intervention.

Why it matters

Potential benefit: If successful, ICUconnect could help ICU teams respond more quickly and consistently to patient and family palliative needs, improving symptom relief and goal-concordant care.

How similar studies have performed: A prior single-center cluster RCT of ICUconnect with 111 patient–family dyads (42% Black) showed significant improvements in unmet needs and goal concordance, so this multicenter RCT builds on promising earlier results.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

Patients (who are not interviewed but whose characteristics prompt enrollment of family members)

1. Adult aged ≥18 years
2. Managed in an adult medical, cardiac, trauma, surgical, or neurological ICU
3. Serious acute illness associated with a need for invasive mechanical ventilation
4. ICU team expect patient to require mechanical ventilation for 2 or more days

Family members

1. Adult aged ≥18 years
2. Family member: self-described as the individual (related or unrelated) who provides the most support and with whom the eligible patient has a significant relationship (Society of Critical Care Medicine definition of family; Davidson J, et al. Crit Care Med, 45:103-128; 2017)

ICU clinicians

1. Adult aged ≥18 years
2. ICU clinician: ICU attending caring for the eligible patient on the day of family member informed consent

Exclusion Criteria:

Patients

1. Death or full comfort care plan expected within 24 hours by ICU attending or fellow physician Rationale: measurable intervention effect unlikely
2. Palliative care consultative team and/or palliative care specialists are currently involved in the patient's care.

   Rationale: this would dilute the intervention's effect.
3. ICU length of stay \>4 days during current ICU admission. Rationale: this would dilute intervention effect by widening the timeframe of family-clinician interactions and limiting standardization.

6\. Imprisoned person. Rationale: this is a vulnerable population.

Family members

1. Low palliative care need burden (i.e., NEST scale score \<15) at baseline. Rationale: if there are very low baseline needs, the intervention cannot impact the primary outcome measure (i.e., NEST).
2. Lack of English or Spanish fluency, operationalized as need for a translator to understand medical forms or participate in medical discussions.

   Rationale: the app has not been translated into other languages; also, many outcome measures aren't validated in languages other than English and Spanish.
3. Endorsement of suicidal ideation (i.e., PHQ-9 suicidality item) at the time of baseline data collection.

   Rationale: this indicates a serious level of distress that will require professional assistance beyond that provided by the intervention (or control).
4. Patient regains decisional capacity after informed consent but before the first family meeting. Rationale: as in our past ICU-based studies, this circumstance (the entry of the patient as a decision maker), would substantially change the nature of the interactions of family members and clinicians.
5. The ICU clinician changes from a consented clinician to a non-consented clinician before the first family meeting. Rationale: in this circumstance the intervention cannot be fully deployed.

ICU clinicians None

Where this trial is running

Birmingham, Alabama and 3 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Critical Illness, Palliative Care, Older Adults, Informal Caregivers, Care Delivery Model

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.